IFIH1 and interstitial lung disease: The indications were as follows: 10 patients received pulse steroids for worsening hypoxemia or progression of ILD, five for worsening cutaneous lesions (anti‐MDA5‐related ulcerations and calcinosis), and three for generalized disease flare, defined as worsening proximal muscle weakness, synovitis, dyspnea, and cutaneous lesions.